14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients

Table 4

Univariate analysis and multivariate analysis of clinicopathologic data and the MSH with OS in the development cohort.

Variables	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	value	Hazard ratio	95% CI	value
Gender (male vs female)	0.725	0.476–1.104	0.134
Age (>60 vs <60)	1.278	0.842–1.273	0.25
BMI (>25 vs <25)	0.849	0.546–1.321	0.469
AFP (>25 vs <25)	1.609	0.955–2.713	0.074
Cirrhosis (yes vs no)	1.013	0.544–1.886	0.967
Child-Pugh stage (B vs A)	1.735	0.812–3.708	0.155
Adjacent tissue inflammation (yes vs no)	1.157	0.647–2.068	0.623
Tumor histologic grade (G3+G4 vs G1+G2)	1.069	0.696–1.64	0.762
Surgical margin status (R1 vs R0)	1.545	0.671–3.558	0.306
AJCC TNM stage (III + IV vs I + II)	1.725	1.093–2.723	0.019
MSH (high risk vs low risk)	4.3	2.691–6.871	0.000	6.355	2.524–16.00	0.000

MSH: methylation signature for HCC.